康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞黄斑水肿

The Clinical application of intravitreous injection of Conbercept combined with laser photocoagulation for Branch retinal vein occlusion with Macula edema

目的观察玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞黄斑水肿的安全性及有效性。方法对36例(36眼)接受玻璃体腔注射康柏西普联合视网膜激光光凝术的视网膜分支静脉阻塞合并黄斑水肿患者的临床资料进行回顾性分析;观察患者治疗后1周、1月、3月的最佳矫正视力、黄斑中心凹视网膜厚度及并发症。结果治疗后1周、1月、3月患者的最佳矫正视力均有不同程度提高,差异有统计学意义(t=7.642、8.501、8.754,P<0.05);光学相关断层扫描检查显示黄斑中心凹视网膜厚度明显变薄,差异有统计学意义(t=4.761、4.543、1.740,P<0.05),未发生严重并发症。结论康柏西普玻璃体腔注射联合视网膜激光光凝治疗视网膜分支静脉阻塞黄斑水肿安全、有效。

Objetive To investigate the effects and safety of intravitreous injection of Conbercept combined with laser photocoagulation for branch retinal vein occlusion（BRVO） with macula edema（ME）. Methods 36 eyes of BRVO with ME were enrolled in this study. All the patients were received loading doses 0.05 ml of injection with Conbercept combined with laser photocoagulation. During the 3 months of follow-up, the changes of post-treatment best corrected visual acuity（BCVA） and central macular thickness（CMT） in pre-therapy and post-treatment were compared, and related complications were recorded. Results There were significant differences of BCVA and CMT in post-treament 1day, 1month and 3months. The numbers of subjects of improving and stabilizing BCVA in every post-treament were more than that in pre-therapy（t=7.642、8.501、8.754, P〈0.05）, The CMTs in every post-treament were thinner than that in pretreatment（t=4.761、 4.543、 1.740, P〈0.05）.And there were no serious complications. Conclusion In the treatment of BRVO with ME, intravitreous injection of Conberecpt combined with laser photocoagulation is effective and safe. It can improve the visual function and relieve ME.